Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Fidelity Advisor Health Care Fund Class M (FACTX) focuses on investing in a diversified portfolio of healthcare-related equities, including pharmaceuticals, biotechnology, and medical devices. Its competitive position is bolstered by Fidelity's extensive research capabilities and a strong track record in fund management, particularly in the healthcare sector.
FACTX generates revenue primarily through management fees based on a percentage of AUM, which allows for scalability as the fund grows. The fund's competitive advantage lies in Fidelity's established brand, extensive research capabilities, and access to a broad range of healthcare investment opportunities.
Changes in healthcare regulations impacting investment opportunities
Performance of underlying healthcare equities in the portfolio
Investor sentiment towards healthcare as a defensive sector
Trends in healthcare spending and innovation
Regulatory changes affecting the healthcare industry
Technological disruption in healthcare delivery and pharmaceuticals
Increased competition from other healthcare-focused funds
Market volatility impacting investor confidence in healthcare investments
Limited financial leverage as a fund, but reliance on market performance of underlying assets
moderate - The healthcare sector tends to be less sensitive to economic cycles, but overall consumer spending and investment trends can influence AUM and inflows.
Rising interest rates could lead to higher borrowing costs for healthcare companies, potentially impacting their stock performance and, in turn, the fund's returns. However, the fund's management fees are less sensitive to interest rate changes.
minimal
growth - Investors looking for exposure to the growing healthcare sector and innovation.
moderate - Historical volatility is generally lower due to the defensive nature of healthcare investments.